Immunovia publ AB (ST:IMMNOV) — Market Cap & Net Worth
Market Cap & Net Worth: Immunovia publ AB (IMMNOV)
Immunovia publ AB (ST:IMMNOV) has a market capitalization of $11.52 Million (Skr107.09 Million) as of September 16, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #26800 globally and #569 in its home market, demonstrating a -5.01% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunovia publ AB's stock price Skr0.16 by its total outstanding shares 672666892 (672.67 Million). Also see Immunovia publ AB balance sheet assets for a full breakdown of the balance sheet.
Immunovia publ AB Market Cap History: 2015 to 2026
Immunovia publ AB's market capitalization history from 2015 to 2026. Data shows change from $2.46 Billion to $11.52 Million (-38.39% CAGR). Also see IMMNOV cash flow conversion for how efficiently the company converts equity into cash flow.
Immunovia publ AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunovia publ AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check IMMNOV live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
23.99x
Immunovia publ AB's market cap is 23.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.66 Billion | $177.28K | -$14.72 Million | 37566.01x | N/A |
| 2017 | $6.35 Billion | $148.96K | -$45.23 Million | 42642.78x | N/A |
| 2018 | $9.98 Billion | $332.60K | -$86.54 Million | 29992.34x | N/A |
| 2019 | $13.00 Billion | $356.00K | -$114.52 Million | 36520.20x | N/A |
| 2020 | $8.63 Billion | $362.00K | -$147.45 Million | 23836.61x | N/A |
| 2021 | $5.43 Billion | $844.00K | -$157.40 Million | 6432.73x | N/A |
| 2022 | $1.90 Billion | $1.15 Million | -$145.03 Million | 1662.75x | N/A |
| 2023 | $128.27 Million | $1.57 Million | -$309.44 Million | 81.44x | N/A |
| 2024 | $39.52 Million | $931.00K | -$76.54 Million | 42.45x | N/A |
| 2025 | $16.43 Million | $685.00K | -$145.91 Million | 23.99x | N/A |
Competitor Companies of IMMNOV by Market Capitalization
Companies near Immunovia publ AB in the global market cap rankings as of September 16, 2026. Review Immunovia publ AB tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Immunovia publ AB by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #88 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #161 globally with a market cap of $147.88 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #476 globally with a market cap of $56.70 Billion USD ( CN¥387.49 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #578 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #88 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $641.39 |
| #161 | Danaher Corporation | NYSE:DHR | $147.88 Billion | $209.36 |
| #476 | WuXi AppTec Co Ltd | SHG:603259 | $56.70 Billion | CN¥156.67 |
| #578 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $350.78 |
Immunovia publ AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Immunovia publ AB's market cap moved from $2.46 Billion to $ 11.52 Million, with a yearly change of -38.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr11.52 Million | -29.87% |
| 2025 | Skr16.43 Million | -58.42% |
| 2024 | Skr39.52 Million | -69.19% |
| 2023 | Skr128.27 Million | -93.26% |
| 2022 | Skr1.90 Billion | -64.93% |
| 2021 | Skr5.43 Billion | -37.08% |
| 2020 | Skr8.63 Billion | -33.63% |
| 2019 | Skr13.00 Billion | +30.33% |
| 2018 | Skr9.98 Billion | +57.04% |
| 2017 | Skr6.35 Billion | -4.62% |
| 2016 | Skr6.66 Billion | +170.59% |
| 2015 | Skr2.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Immunovia publ AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.52 Million USD |
| MoneyControl | $11.52 Million USD |
| MarketWatch | $11.52 Million USD |
| marketcap.company | $11.52 Million USD |
| Reuters | $11.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immunovia publ AB
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.